Targeted therapies have been shown to be of benefit for some patients whose tumours carry specific mutations [5]: Pemigatinib, a pan-FGFR inhibitor, is of value to patients with FGFR2 gene rearrangements [6]; Larotrectinib and Entrectinib, neurotrophic receptor tyrosine kinases (NTRK) inhibitors, are effective in patients with NTRK fusion-positive cancers [7]; Pertuzumab plus Trastuzumab is useful for patients with HER2 amplification [8]; and Ivosidenib is beneficial to patients with IDH1 mutated CCA [9]. This evidence concerns the gene ERBB2 and cancer.